Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity

CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma

(2012) L. Wu et al.   MOLECULAR CANCER THERAPEUTICS

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice

(2011) B. L. Mundy-Bosse et al.   CANCER RESEARCH

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

(2010) Lorna Rettig et al.   INTERNATIONAL JOURNAL OF CANCER

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

(2010) Rupal Ramakrishnan et al.   JOURNAL OF CLINICAL INVESTIGATION

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

(2010) I Martins et al.   ONCOGENE

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

(2010) V. A. Pedicord et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Ipilimumab: controversies in its development, utility and autoimmune adverse events

(2009) Jeffrey Weber   CANCER IMMUNOLOGY IMMUNOTHERAPY

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA